Figure 4From: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusSELENA SLEDAI scores. The SELENA SLEDAI scores in the single-dose and double-dose cohorts over time are presented, stratified by baseline SELENA SLEDAI score (≥4 or <4). Values are expressed as mean ± standard error. SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.Back to article page